A Comparative Study of the Efficacy of Multimodal Interventions for Tenosynovitis

Key facts

Sponsor

Zixin Deng

Principal Investigator

Xin Z Deng, R.N

Intervention

Basic Manipulation Stretching(behavioral)

Enrollment

45 target

Eligibility

18-60 years · All sexes

Timeline

2024 – 2025

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tenosynovial giant cell tumor

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07499362
  Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
  Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
• RECRUITINGPHASE4NCT07315841
  Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
  Shanghai Jiao Tong University Affiliated Sixth People's Hospital
• RECRUITINGNCT07075471
  Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
  Deciphera Pharmaceuticals, LLC
• ACTIVE NOT RECRUITINGPHASE3NCT05417789
  Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
  SynOx Therapeutics Limited
• ACTIVE NOT RECRUITINGPHASE3NCT05804045
  Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
  Abbisko Therapeutics Co, Ltd
• ACTIVE NOT RECRUITINGPHASE3NCT05059262
  Study of Vimseltinib for Tenosynovial Giant Cell Tumor
  Deciphera Pharmaceuticals, LLC
• ACTIVE NOT RECRUITINGPHASE2NCT04703322
  A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
  Daiichi Sankyo Co., Ltd.
• RECRUITINGNCT04635111
  A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
  Daiichi Sankyo

See all trials for Tenosynovial giant cell tumor →